Zealand Pharma A/S (ZLDPF) Lowered to Sell at Zacks Investment Research
Zealand Pharma A/S (NASDAQ:ZLDPF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.
According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company’s pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark. “
Shares of Zealand Pharma A/S (NASDAQ ZLDPF) traded down 2.64% during midday trading on Tuesday, hitting $18.45. 1 shares of the company traded hands. The stock’s market capitalization is $472.50 million. Zealand Pharma A/S has a 52 week low of $14.95 and a 52 week high of $19.51. The company has a 50-day moving average price of $18.70 and a 200-day moving average price of $17.63.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.